Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670521 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL22533708 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL4614360 | 0.86 | KDM4E (0.45) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL5727824 | 0.86 | KDM4E (0.45) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL2086312 | 0.86 | KDM4E (0.45) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| Hydrochloric Acid SCHEMBL8126191 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| Hydrochloric Acid SCHEMBL4677792 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL27659401 | 0.81 | ALDH1A1 (0.41) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL4670053 | 0.81 | AOC3 (0.44) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL27659402 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1L3MBTL1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465842-B2 | Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1054881-B1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20060046287-A1 | Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| US-6903218-B2 | Sulfonamide substituted chroman derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | LADOUCEUR GAETAN H (US) | 2004-04-15 | — | — | US | disclosed |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | BAYER PHARMACEUTICALS CORPORATION | 2003-04-17 | — | — | US | disclosed |
| US-6451587-B1 | ASYMMETRIC REDUCTION OF A KETONE TO AN ALCOHOL, WHICH COMPRISES: CONTACTING THE KETONE WITH A MICROORGANISM, OR AN ENZYME REDUCTION SYSTEM CAPABLE OF ACCOMPLISHING THE SUBJECT REDUCTION COMPRISING AN ENZYME DERIVED FROM SAID MICROORGANISM | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-6051586-A | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | BAYER CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | KDM4E 4058/4885ALDH1A1 1908/4885L3MBTL1 4385/4885 |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | ADRB3, ADRB2, ADRB1 | KDM4E 4659/4885ALDH1A1 1879/4885L3MBTL1 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.